Beginners’ Portfolio Ahead, Despite Being Held Back By BP plc, Rio Tinto plc And GlaxoSmithKline plc

BP plc (LON: BP), Rio Tinto plc (LON: RIO) and GlaxoSmithKline plc (LON: GSK) weren’t as safe as I thought!

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

This article is the latest in a series that aims to help novice investors with the stock market. To enjoy past articles in the series, please visit our full archive.

The Beginners’ Portfolio is a virtual portfolio, run as if based on real money with all costs, spreads and dividends accounted for. Transactions made for the portfolio are for educational purposes only and do not constitute advice to buy or sell.

As of market close on 12 November, the Beginners’ Portfolio is up 34% since inception including all costs — the FTSE 100 is up approximately 27% over the same period, including dividends. When I started out, I went for a mix of what I saw as safe blue-chip stocks, together with some riskier high-tech growth ones — and ironically, it’s these “safe” ones that have held us back and we have the growth stars to thank for our outperformance.

Oil crunch

When I added BP (LSE: BP) to the portfolio in August 2012, the big risk I saw was that the Gulf of Mexico disaster could hang over the company for some time, and things actually turned out worse than I expected on that score. But that’s not the reason behind the 20% share price fall since purchase, to 366p.

No, it’s the oil price crash, of course. Back then, Brent Crude was up over $110 a barrel, while today it’s down around $45. BP has offloaded assets, shelved expensive developments, and essentially entrenched to sit out the storm. The big saving grace is that BP has managed to maintain its dividend, and that has offset the share price fall — and we’re down only a couple of percent overall.

The dividend won’t be covered by forecast earnings this year or next, but BP seems very keen to keep the annual payment going, and I’m reasonably confident we’ll get the 6.5% on offer.

Commodities crash

The Rio Tinto (LSE: RIO) story has been a worse one, with the shares down 31% to 2,238p. In this case dividends have helped a little, but we’re still looking at an overall loss of 21%.

The commodities crisis has simply gone on much longer than I feared and has bitten much harder, and what started as a relatively small oversupply of things like iron and copper has been exacerbated by slowing Chinese demand. And the analysts don’t see any end to it yet, with a 50% fall in EPS forecast for this year and a more modest single-digit drop to follow in 2016.

What to do now? I’m just gritting my teeth and hanging on. The cycle will come back, demand will one day exceed supply once more, and metals (and miners) prices will rise again. I’ve no idea when, mind, but I reckon I’d be mad to sell now.

Pharma rebound?

One of my big early hopes was GlaxoSmithKline (LSE: GSK), and I thought I was adding it to the portfolio at a period of serious pessimism back in June 2012 as patents were expiring and generic competition was hotting up. The firm’s financial clout and its beefed up investments in rebuilding its drugs research pipeline would, I was confident, get the pharmaceuticals behemoth back to growth before too many years were out.

I still think that, although the market seems to have lost its patience with Glaxo — at 1,330p, the share price had fallen 12% since purchase (and it’s further down as I write, the day after my valuation snapshot was taken). In this case, dividends have actually turned that loss into a modest 5% gain, so it’s the least disastrous of these three.

And forecasts are still on for a return to EPS growth next year — a year sooner than many were thinking just a couple of years ago. And you know what? On a forward P/E of 16 based on 2016 forecasts, Glaxo could even be a takeover target!

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »